Bill > HB4640

This bill amends West Virginia law regarding controlled substances by adding a provision to §60A-2-201 that allows for the lawful prescription, distribution, and marketing of crystalline polymorph psilocybin if it is approved by the United States Food and Drug Administration (FDA) and rescheduled by the United States Drug Enforcement Administration (DEA). The bill also makes conforming changes to §60A-2-204, which lists substances in Schedule I of controlled substances, by explicitly exempting psilocybin that meets these FDA and DEA criteria from Schedule I classification. This means that if a specific form of psilocybin receives federal approval for medical use, it can be legally handled in West Virginia according to those federal guidelines, rather than being automatically prohibited as a Schedule I substance.

Health and Social Services

http://www.wvlegislature.gov/Bill_Status/Bills_history.cfm?input=4640&year=2026&sessiontype=RS&btype=bill